 | Here's a couple of stock ideas I'm looking at for next week. These are companies I'll consider investing in with any funds that become available in my accounts. I believe each of these has a greater potential return than analysts currently expect. As with all of my investments, I'll start with a small position and then add to that position over time through dividend reinvestment, the sale of stock options and direct purchases on the open market. |
Overstock.com, Inc. operates as an online retailer in the United States. The company operates through two segments, Direct and Partner. It offers brand name, non-brand name, and closeout products, including furniture, home decor, bedding and bath, housewares, jewelry and watches, apparel and designer accessories, health and beauty products, electronics and computers, and sporting goods, among other products; and sells various books, magazines, CDs, DVDs, and video games. The company also provides handcraft, fresh produce and other food, and insurance products. Overstock.com, Inc. sells its products and services through its Internet Websites located at overstock.com, o.co, and o.biz, as well as through the United States based third party logistics providers to international customer. The company was formerly known as D2-Discounts Direct and changed its name to Overstock.com, Inc. in October 1999. Overstock.com, Inc. was founded in 1997 and is based in Midvale, Utah.
(Summary) (Company) (Chart)
(Summary) (Company) (Chart)
| 28 January 2018 Price $74.45 1yr Target $110.00 Analysts 1 Dividend $0.00 Payout Ratio 0.00% 1yr Cap Gain 47.75% Yield 0.00% 1yr Tot Return 47.75% P/E --- PEG --- Beta 1.53 | EPS (ttm) $-0.43 EPS next yr $-0.51 Forward P/E --- EPS next 5yr 4.00% 1yr Price Support --- Market Cap $1.71 Bil Revenues $1.81 Bil Earnings $-10.80 Mil Profit Margin --- Quick Ratio 0.80 Current Ratio 0.90 Debt/Equity 0.34 | 1yr RevGR 8.56% 3yr RevGR 11.20% 5yr RevGR 11.28% 1yr EarnGR 390.00% 3yr EarnGR -47.59% 5yr EarnGR --- 1yr DivGR --- 3yr DivGR --- 5yr DivGR --- ROA -2.50% ROE -6.40% |
NovoCure Limited engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) for the treatment of solid tumors. The company markets its proprietary therapy, TTFields delivery system under the Optune name for use as a monotherapy treatment for adult patients with glioblastoma brain cancer. It is also involved in conducting clinical trials for the use of TTFields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, and mesothelioma. The company markets its products in the United States, Germany, Switzerland, Japan, and other countries. NovoCure Limited was founded in 2000 and is based in Saint Helier, the Channel Islands.
(Summary) (Company) (Chart)
(Summary) (Company) (Chart)
| 28 January 2018 Price $23.65 1yr Target $27.00 Analysts 5 Dividend $0.00 Payout Ratio 0.00% 1yr Cap Gain 14.16% Yield 0.00% 1yr Tot Return 14.16% P/E --- PEG --- Beta --- | EPS (ttm) $-0.83 EPS next yr $0.11 Forward P/E 223.11 EPS next 5yr 60.00% 1yr Price Support $6.60 Market Cap $2.07 Bil Revenues $153.60 Bil Earnings $-72.90 Mil Profit Margin --- Quick Ratio 5.30 Current Ratio 5.90 Debt/Equity 0.83 | 1yr RevGR --- 3yr RevGR --- 5yr RevGR --- 1yr EarnGR --- 3yr EarnGR --- 5yr EarnGR --- 1yr DivGR --- 3yr DivGR --- 5yr DivGR --- ROA -27.30% ROE -57.70% |
Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is also developing Korlym in combination with eribulin, which is in Phase I/II clinical trial to treat patients with metastatic triple-negative breast cancer; Korlym in combination with drug Abraxane that is in Phase II clinical trial to treat patients with triple-negative breast cancer; and Korlym combined with the androgen deprivation agent enzalutamide, which is in Phase II clinical trial to treat patients with metastatic castration-resistant prostate cancer. In addition, it develops CORT125134 for the treatment of patients with Cushing's syndrome and solid-tumor cancers; and CLIA-validated assay to measure expression of the gene FKBP5, which is stimulated by cortisol activity at glucocorticoid receptor. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.
(Summary) (Company) (Chart)
(Summary) (Company) (Chart)
| 28 January 2018 Price $25.10 1yr Target $20.75 Analysts 4 Dividend $0.00 Payout Ratio 0.00% 1yr Cap Gain -17.34% Yield 0.00% 1yr Tot Return -17.34% P/E 87.46 PEG 1.23 Beta 1.69 | EPS (ttm) $0.29 EPS next yr $0.88 Forward P/E 28.69 EPS next 5yr 71.00% 1yr Price Support $62.48 Market Cap $2.82 Bil Revenues $129.70 Mil Earnings $35.40 Mil Profit Margin 27.29% Quick Ratio 3.70 Current Ratio 3.90 Debt/Equity 0.00 | 1yr RevGR 61.71% 3yr RevGR 97.39% 5yr RevGR --- 1yr EarnGR --- 3yr EarnGR --- 5yr EarnGR --- 1yr DivGR --- 3yr DivGR --- 5yr DivGR --- ROA 41.50% ROE 58.20% |
Momo Inc. operates as a mobile-based social networking platform in the People’s Republic of China. The company’s platform includes its Momo mobile application and various related features, functionalities, tools, and services that are provided to users, customers, and platform partners. It offers Momo mobile application that enables users to establish and expand their social relationships based on locations and interests; and Hani, a live video application. The company also offers games, which are designed with various themes, cultural characteristics, and features to appeal to various segments of the game player community; paid emoticons, and mobile marketing services; and live video, value-added, and other services. The company was formerly known as Momo Technology Company Limited and changed its name to Momo Inc. Momo Inc. was founded in 2011 and is headquartered in Beijing, the People’s Republic of China.
(Summary) (Company) (Chart)
(Summary) (Company) (Chart)
| 28 January 2018 Price $30.30 1yr Target $39.06 Analysts 17 Dividend $0.00 Payout Ratio 0.00% 1yr Cap Gain 28.91% Yield 0.00% 1yr Tot Return 28.91% P/E 20.58 PEG 0.45 Beta --- | EPS (ttm) $1.47 EPS next yr $2.14 Forward P/E 14.15 EPS next 5yr 45.52% 1yr Price Support $97.41 Market Cap $5.77 Bil Revenues $1.18 Bil Earnings $304.80 Mil Profit Margin 25.76% Quick Ratio 5.00 Current Ratio 5.00 Debt/Equity 0.00 | 1yr RevGR --- 3yr RevGR --- 5yr RevGR --- 1yr EarnGR --- 3yr EarnGR --- 5yr EarnGR --- 1yr DivGR --- 3yr DivGR --- 5yr DivGR --- ROA 32.40% ROE 39.60% |
RSS Feed
